Anaptysbio (ANAB) Prepaid Assets (2016 - 2026)
Anaptysbio's (ANAB) quarterly Prepaid Assets came in at $3.9 million in Q1 2026, down 26.17% YoY from $5.3 million in Q1 2025, and down 17.95% on a QoQ basis from $4.8 million in Q4 2025.
Analysis
Anaptysbio (ANAB) Prepaid Assets (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Prepaid Assets data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Prepaid Assets fell 26.17% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 26.17% YoY) and the FY2025 annual result came in at $4.8 million, down 17.01% from the prior year.
- Prepaid Assets fell to $3.9 million in Q1 2026, from $4.8 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $11.7 million in Q3 2023 to a low of $3.9 million in Q1 2026.
- A 5-year average of $6.6 million and a median of $5.9 million in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets surged 138.08% — and 2025, when it plunged 50.38%.
- Tracing ANAB's Prepaid Assets over 5 years: stood at $4.5 million in 2022, then soared by 99.78% to $9.1 million in 2023, then slumped by 36.81% to $5.7 million in 2024, then slipped by 17.01% to $4.8 million in 2025, then fell by 17.95% to $3.9 million in 2026.
- The last three Prepaid Assets figures came in at $3.9 million (Q1 2026), $4.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.91 Mn |
| Dec 31, 2025 | 4.76 Mn |
| Sep 30, 2025 | 6.01 Mn |
| Jun 30, 2025 | 4.78 Mn |
| Mar 31, 2025 | 5.29 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Sep 30, 2024 | 6.37 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Mar 31, 2024 | 10.67 Mn |
| Dec 31, 2023 | 9.08 Mn |
| Sep 30, 2023 | 11.68 Mn |
| Jun 30, 2023 | 5.87 Mn |
| Mar 31, 2023 | 4.48 Mn |
| Dec 31, 2022 | 4.55 Mn |
| Sep 30, 2022 | 6.30 Mn |
| Jun 30, 2022 | 9.63 Mn |
| Mar 31, 2022 | 5.87 Mn |
| Dec 31, 2021 | 4.90 Mn |
| Sep 30, 2021 | 11.76 Mn |
| Jun 30, 2021 | 6.51 Mn |